Rani Therapeutics Hldgs Analyst Ratings
Rani Therapeutics Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 661.58% | HC Wainwright & Co. | $20 → $16 | Maintains | Buy |
| 09/20/2023 | 851.97% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 09/08/2023 | 851.97% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 08/21/2023 | 709.18% | B of A Securities | $19 → $17 | Maintains | Buy |
| 08/17/2023 | 851.97% | Wedbush | → $20 | Reiterates | Outperform → Outperform |
| 08/14/2023 | 851.97% | HC Wainwright & Co. | $22 → $20 | Maintains | Buy |
| 06/06/2023 | 947.17% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy |
| 05/11/2023 | 947.17% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy |
| 03/23/2023 | 947.17% | HC Wainwright & Co. | → $22 | Reiterates | → Buy |
| 10/11/2022 | 613.98% | UBS | → $15 | Initiates Coverage On | → Buy |
| 07/27/2022 | 947.17% | HC Wainwright & Co. | → $22 | Initiates Coverage On | → Buy |
| 06/13/2022 | 1232.76% | Wedbush | → $28 | Initiates Coverage On | → Outperform |
| 08/25/2021 | 1042.37% | BTIG | → $24 | Initiates Coverage On | → Buy |
| 08/24/2021 | 994.77% | B of A Securities | → $23 | Initiates Coverage On | → Buy |
| 08/24/2021 | 994.77% | Cantor Fitzgerald | → $23 | Initiates Coverage On | → Overweight |
| 08/24/2021 | 1042.37% | Stifel | → $24 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/09/2023 | 661.58% | HC Wainwright & Co. | 20 美元 → 16 美元 | 維護 | 買 |
| 09/20/2023 | 851.97% | HC Wainwright & Co. | → 20 美元 | 重申 | 購買 → 購買 |
| 09/08/2023 | 851.97% | HC Wainwright & Co. | → 20 美元 | 重申 | 購買 → 購買 |
| 08/21/2023 | 709.18% | B of A 類證券 | 19 美元 → 17 美元 | 維護 | 買 |
| 08/17/2023 | 851.97% | Wedbush | → 20 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 08/14/2023 | 851.97% | HC Wainwright & Co. | 22 美元 → 20 美元 | 維護 | 買 |
| 06/06/2023 | 947.17% | HC Wainwright & Co. | → 22 美元 | 重申 | 購買 → 購買 |
| 05/11/2023 | 947.17% | HC Wainwright & Co. | → 22 美元 | 重申 | 購買 → 購買 |
| 03/23/2023 | 947.17% | HC Wainwright & Co. | → 22 美元 | 重申 | → 購買 |
| 2022 年 10 月 11 日 | 613.98% | 瑞銀（UBS） | → 15 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/27/2022 | 947.17% | HC Wainwright & Co. | → 22 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 06/13/2022 | 1232.76% | Wedbush | → 28 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 8 月 25 日 | 1042.37% | BTIG | → 24 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/24/2021 | 994.77% | B of A 類證券 | → 23 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/24/2021 | 994.77% | 坎託·菲茨傑拉德 | → 23 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 08/24/2021 | 1042.37% | Stifel | → 24 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Rani Therapeutics Hldgs (RANI)?
Rani Therapeutics Hldgs（RANI）的目標價格是多少？
The latest price target for Rani Therapeutics Hldgs (NASDAQ: RANI) was reported by HC Wainwright & Co. on November 9, 2023. The analyst firm set a price target for $16.00 expecting RANI to rise to within 12 months (a possible 661.58% upside). 9 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月9日公佈了Rani Therapeutics Hldgs（納斯達克股票代碼：RANI）的最新目標股價。該分析公司將目標股價定爲16.00美元，預計RANI將在12個月內升至12個月內（可能上漲661.58％）。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Rani Therapeutics Hldgs (RANI)?
Rani Therapeutics Hldgs（RANI）的最新分析師評級是多少？
The latest analyst rating for Rani Therapeutics Hldgs (NASDAQ: RANI) was provided by HC Wainwright & Co., and Rani Therapeutics Hldgs maintained their buy rating.
Rani Therapeutics Hldgs（納斯達克股票代碼：RANI）的最新分析師評級由HC Wainwright & Co. 提供，Rani Therapeutics Hldgs維持買入評級。
When is the next analyst rating going to be posted or updated for Rani Therapeutics Hldgs (RANI)?
Rani Therapeutics Hldgs（RANI）的下一份分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rani Therapeutics Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rani Therapeutics Hldgs was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Rani Therapeutics Hldgs的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Rani Therapeutics Hldgs的最新評級是在2023年11月9日公佈的，因此您應該預計下一個評級將在2024年11月9日左右公佈。
Is the Analyst Rating Rani Therapeutics Hldgs (RANI) correct?
分析師對Rani Therapeutics Hldgs（RANI）的評級是否正確？
While ratings are subjective and will change, the latest Rani Therapeutics Hldgs (RANI) rating was a maintained with a price target of $20.00 to $16.00. The current price Rani Therapeutics Hldgs (RANI) is trading at is $2.10, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Rani Therapeutics Hldgs（RANI）評級維持不變，目標股價爲20.00美元至16.00美元。Rani Therapeutics Hldgs（RANI）目前的交易價格爲2.10美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。